MedTrace Logo

A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects

NCT03989544 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2020-01-09

No results posted yet for this study

Summary

This is a study to compare PK of tezepelumab exposure in healthy subjects by using vial and syringe, APFS, and AI.

Conditions

Interventions

BIOLOGICAL

Tezepelumab

Tezepelumab subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Dr. Rainard Fuhr · Parexel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-19
Primary Completion
2019-12-30
Completion
2019-12-30
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03989544 on ClinicalTrials.gov